1. Henri A Termeer was a Dutch biotechnology executive and entrepreneur.
18 Facts About Henri Termeer
1. 2.
Henri Termeer served as CEO at Genzyme from 1981 to 2011.
3.
Henri Termeer was "connected to 311 board members in 17 different organizations across 20 different industries".
4.
Henri Termeer was named as one of the top 50 people who have advanced rare disease research, in a list produced by Terrapin for the World Orphan Drug Congress.
5.
Henri Termeer received an honorary Doctor of Science from the University of Massachusetts.
6.
Henri Termeer began his career in the medical and healthcare industry in 1973 when he started working as manager of international product planning for Deerfield, Illinois-based Travenol Laboratories Inc now known as Baxter.
7.
In 1983, Henri Termeer joined Genzyme, a two-year-old start-up biotechnology company located in Cambridge, Massachusetts.
8.
When Genzyme needed a manufacturing facility, Henri Termeer chose to remain in Massachusetts and use local contractors instead of joining the pharmaceuticals cluster in the New Jersey and Philadelphia areas.
9.
Henri Termeer explained in a 2005 interview for The Wall Street Journal that, in 1991, one treatment of Cerezyme for one patient took 22,000 placentas annually to manufacture, a difficult and expensive procedure.
10.
In 1981, before Henri Termeer had joined Genzyme, it was a small firm that employed 14 people in an office in Chinatown.
11.
In 2004 Henri Termeer was the area's highest-paid CEO, with a total compensation package worth at least $37.9 million.
12.
Henri Termeer was 42nd in the 2006 list of Boston's wealthiest with a net worth of $342 million.
13.
Henri Termeer was fined $175 million by the FDA for manufacturing deficiencies.
14.
When Henri Termeer left Genzyme his payout was valued at about $138 million.
15.
In 1993, Henri Termeer helped establish the Biotechnology Industry Organization, and joined the board of directors.
16.
In 2002 Henri Termeer was involved in the establishment of the New England Healthcare Institute, a "nonprofit, applied research health policy organization" composed of senior healthcare experts and executives.
17.
Henri Termeer was a Chairman Emeritus of the New England Healthcare Institute.
18.
Henri Termeer joined a group of executives providing financial backing for ProQR, which has subsequently pivoted to inherited retinal diseases including Leber congenital amaurosis, Usher syndrome and retinitis pigmentosa.